129 related articles for article (PubMed ID: 10766426)
1. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer Lett; 2000 Apr; 151(1):81-6. PubMed ID: 10766426
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
[TBL] [Abstract][Full Text] [Related]
3. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
4. Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Miyagi Y
Gastric Cancer; 2006; 9(2):106-13. PubMed ID: 16767366
[TBL] [Abstract][Full Text] [Related]
5. Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer.
Yoshikawa T; Cho H; Tsuburaya A; Kobayashi O
Gastric Cancer; 2009; 12(1):31-6. PubMed ID: 19390929
[TBL] [Abstract][Full Text] [Related]
6. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis.
Yoshikawa T; Saitoh M; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer; 1999 Nov; 86(10):1929-35. PubMed ID: 10570415
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma a new biomartker for invasion and its impact on survival.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y
Cancer; 2001 May; 91(9):1739-44. PubMed ID: 11335899
[TBL] [Abstract][Full Text] [Related]
8. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in peripheral blood of patients with gastric carcinoma].
Yoshikawa T; Suzuki K; Kobayashi O; Sairenji M; Motohashi H; Yanoma S; Noguchi Y; Tsuburaya A
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1461-4. PubMed ID: 9703854
[TBL] [Abstract][Full Text] [Related]
10. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma.
Zhang S; Li L; Lin JY; Lin H
World J Gastroenterol; 2003 May; 9(5):899-904. PubMed ID: 12717827
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer.
Kushlinskii NE; Gershtein ES; Ivannikov AA; Davydov MM; Chang VL; Ognerubov NA; Stilidi IS
Bull Exp Biol Med; 2019 Jan; 166(3):373-376. PubMed ID: 30627896
[TBL] [Abstract][Full Text] [Related]
12. Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer.
Kemik O; Kemik AS; Sümer A; Dulger AC; Adas M; Begenik H; Hasirci I; Yilmaz O; Purisa S; Kisli E; Tuzun S; Kotan C
World J Gastroenterol; 2011 Apr; 17(16):2109-12. PubMed ID: 21547130
[TBL] [Abstract][Full Text] [Related]
13. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T
Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma.
Gaspar MJ; Arribas I; Coca MC; Díez-Alonso M
Tumour Biol; 2001; 22(5):318-22. PubMed ID: 11553862
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
17. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients.
Adachi Y; Tsuchihashi J; Shiraishi N; Yasuda K; Etoh T; Kitano S
Oncology; 2003; 65(2):95-101. PubMed ID: 12931013
[TBL] [Abstract][Full Text] [Related]
18. [Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas].
Li L; Zhang S; Lin H; Lin JY
Ai Zheng; 2002 Mar; 21(3):305-10. PubMed ID: 12452001
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
[TBL] [Abstract][Full Text] [Related]
20. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
